Common Contracts
1 similar Investigator Agreement contracts
INVESTIGATOR AGREEMENTInvestigator Agreement • October 14th, 2021
In every cohort, a loading dose of KPL-716 at 720 mg SC (or matching placebo) will be followed by maintenance doses of 360 mg SC (or matching placebo) administered every week for 7 additional weekly doses in order to detect an early signal of efficacy on pruritus once exposures approach an expected steady state. In addition, the impact of KPL-716 on sleep and quality of life will be assessed. Furthermore, the impact of KPL-716 on urticaria in CIU (Cohort 1) will be investigated.
